NCT05624580View on ClinicalTrials.gov

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

October 16, 2025

Study Completion Date

October 16, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

NNC0582-0001

Participants will receive single dose of any of the six dose levels of subcutaneous NNC0582-0001 in a sequential manner with the dose increasing between cohorts.

DRUG

Placebo

Participants will receive single dose of subcutaneous injection of placebo matched to NNC0582-0001.

Trial Locations (1)

8010

Clinical Trials Unit / Center for Medical Research, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY